Nelson Vergel
Founder, ExcelMale.com
By Reuters Staff
The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.
The FDA has called for a joint meeting of the bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee.
Send the FDA your comments by sending an email to address provided in this link: (http://1.usa.gov/1nPA7Qf)
In June, the FDA said that all testosterone products on the market should include in their labels a general warning about the risk of blood clots in veins.
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.
The FDA has called for a joint meeting of the bone, reproductive and urologic drugs advisory committee and the drug safety and risk management advisory committee.
Send the FDA your comments by sending an email to address provided in this link: (http://1.usa.gov/1nPA7Qf)
In June, the FDA said that all testosterone products on the market should include in their labels a general warning about the risk of blood clots in veins.
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
